Cutaneous Lupus Medication Experience Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

11 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-12-31

Study Completion Date

2020-12-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cutaneous lupus is a chronic, relapsing, auto-immune skin disease that can have many presentations. Its effect on physical appearance greatly affects patients' quality of life. In addition, 10% of patients with cutaneous lupus will develop systemic lupus. Topical therapies are the mainstay of cutaneous lupus treatment; however patients often find these treatments to be messy, inconvenient, or ineffective. In addition, for more severe disease patients are often placed on concurrent systemic therapies. The primary hypothesis of our study is that poor adherence contributes to poor treatment outcomes in patients with cutaneous lupus.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus

NCT03288324

Cutaneous Lupus Systemic Lupus Erythematosus

COMPLETED PHASE1/PHASE2

To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus

NCT01300208

Cutaneous Lupus Erythematosus

COMPLETED PHASE2

Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus

NCT06261021

Discoid Lupus Erythematosus

RECRUITING PHASE2

A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus

NCT05866861

Systemic Lupus Erythematosus SLE (Systemic Lupus) Autoimmune

ACTIVE_NOT_RECRUITING PHASE1

Efficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE)

NCT00317681

Cutaneous Lupus Erythematosus

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cutaneous lupus is a chronic, relapsing auto-immune disease that negatively impacts patients' quality of life. As there are many safe topical therapies that require daily use to be effective, and adherence to medication remains a common problem in dermatology, it is worthwhile to reliably measure adherence to medication in patients with cutaneous lupus. By elucidating barriers to effective control of cutaneous lupus with topical medications, we can improve patient care and guide interventions that will avoid the use of systemic therapy which often has more side effects.

The primary aim is to determine adherence to topical and systemic lupus treatment. Subjects will receive standard of care therapy (low potency and high potency topical corticosteroids) and systemic therapy when clinically appropriate. Adherence to medications will be monitored electronically in all subjects. The following hypothesis is to be tested: Non-adherence to topical and systemic medication contributes to treatment failure in patients with cutaneous lupus.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cutaneous Lupus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lupus control standard-of-care

Each person enrolled will be given fluocinonide 0.05% cream to apply twice daily to active areas.

fluocinonide 0.05% cream

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fluocinonide 0.05% cream

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Any male or female 12 years or older of age with a diagnosis of cutaneous lupus by a dermatologist
* Capable of understanding and willing to provide a signed and dated written voluntary informed consent before any protocol specific procedures are performed
* Able to complete the study and comply with study instructions, including attending all study visits

Exclusion Criteria

* Individuals younger than 12 years of age
* Known allergy or sensitivity to study medication
* Inability to complete all study-related visits
* Introduction of any other prescription medication, topical or systemic, for cutaneous lupus while participating in the study

Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No